Trending Topics in Gastroenterology | GastroAGI

AFP-L3 or DCP expression is associated with poor outcomes in unresectable HCC

Yes, the expression of AFP-L3 or DCP is strongly associated with poor outcomes in patients with unresectable hepatocellular carcinoma (HCC), as demonstrated by the study you referenced. Here's a detailed explanation of why these biomarkers are significant and how their expression correlates with prognosis: ### What is AFP-L3 and How is it Different from AFP? - **AFP (Alpha-fetoprotein):** AFP is a glycoprotein produced primarily by the fetal liver and yolk sac during development. In adults, elevated AFP levels are commonly associated with liver diseases such as hepatitis, cirrhosis, and HCC. However, AFP alone has limitations as a biomarker because up to half of early-stage HCC patients have normal AFP levels, making it insufficient for accurate risk stratification. - **AFP-L3 (Lens culinaris agglutinin-reactive AFP):** AFP-L3 is a specific isoform of AFP that is bound to a lectin called Lens culinaris agglutinin. Unlike total AFP, AFP-L3 is more specific to malignant hepatocytes and is considered a highly sensitive marker for HCC. It is especially useful in detecting aggressive and invasive tumor phenotypes. Elevated AFP-L3 levels have been associated with poorer prognosis, higher recurrence rates, and greater likelihood of vascular invasion. ### What is DCP (Des-gamma-carboxyprothrombin)? - **DCP:** DCP, also known as PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II), is an abnormal form of prothrombin that arises due to defective post-translational carboxylation in malignant hepatocytes. It is a well-recognized biomarker for HCC and is associated with tumor progression, angiogenesis, and metastasis. DCP is particularly useful in detecting HCC in patients with normal AFP levels and in predicting poor outcomes. ### Why Are AFP-L3 and DCP Helpful for Prognosis in Unresectable HCC? - **Detection of Aggressive Tumor Biology:** Persistent AFP-L3 and DCP expression after liver-directed therapy (LDT) indicates the presence of viable, aggressive tumor tissue that may not be detectable through imaging. These biomarkers are associated with more invasive and advanced disease phenotypes. - **Prognostic Value Beyond Imaging:** While imaging techniques like CT or MRI are critical for assessing tumor response, they may not capture microscopic or indeterminate residual disease. Biomarkers like AFP-L3 and DCP provide additional, independent prognostic information about the biological activity of the tumor. - **Risk Stratification:** Patients with AFP-L3 and/or DCP positivity have a significantly higher risk of disease progression and worse survival outcomes compared to those with negative biomarker profiles. This allows for early identification of high-risk patients who may require more aggressive or alternative treatment strategies. ### Association of AFP-L3/DCP Expression with Poor Outcomes in Unresectable HCC 1. **Incomplete Response to LDT:** - Patients with persistent AFP-L3 or DCP positivity after LDT (e.g., Yttrium-90 radioembolization, microwave ablation, or chemoembolization) are less likely to achieve a complete radiographic response. Only 29% of biomarker-positive patients achieved a complete response compared to 64% of triple-negative patients (AFP, AFP-L3, and DCP all negative). 2. **Higher Risk of Disease Progression:** - Persistent AFP-L3/DCP positivity was associated with dramatically increased rates of disease progression: - 1-year progression rate: 39% in biomarker-positive patients vs. 8% in biomarker-negative patients. - 2-year progression rate: 66% in biomarker-positive patients vs. 10% in biomarker-negative patients. - Median time-to-progression (TTP) was only 18 months in biomarker-positive patients, whereas it was not reached in biomarker responders (triple-negative patients). 3. **Poor Overall Survival (OS):** - Two-year OS was significantly worse in biomarker-positive patients (62%) compared to biomarker-negative patients (81%). - Patients with AFP-L3+/DCP+ phenotypes had the worst outcomes, with a 10.8-fold higher progression risk compared to triple-negative or AFP-only groups, even after adjusting for competing risks. 4. **Phenotypic Subgroups and Survival:** - The AFP+ AFP-L3+/DCP+ subgroup had the poorest outcomes, with a 2-year OS of only 36%, which is similar to survival rates seen in advanced HCC (BCLC-C stage), despite their earlier clinical stage (BCLC A–B). - In contrast, patients with only AFP positivity but negative AFP-L3 and DCP had outcomes comparable to triple-negative patients, highlighting the importance of distinguishing isolated AFP elevation from multi-biomarker positivity. 5. **Shorter Time-to-Progression in Incomplete Responders:** - Among patients with incomplete radiographic response to LDT, those with AFP-L3+/DCP+ expression had a median TTP of only 9 months, compared to 63 months in patients with AFP-only or triple-negative profiles. ### Biological Interpretation - Persistent AFP-L3 and/or DCP positivity likely reflects residual tumor activity that is not fully eradicated by LDT. These biomarkers may signify the presence of viable but radiographically indeterminate tumor tissue, which could explain the higher rates of progression and poorer survival outcomes. - The inferior outcomes associated with AFP-L3/DCP expression were independent of liver function parameters, such as Child–Pugh score, bilirubin, or albumin levels, suggesting that these biomarkers provide prognostic information beyond hepatic reserve or liver dysfunction. ### Clinical Implications 1. **Routine Multi-Biomarker Testing:** - Incorporating AFP-L3 and DCP testing alongside AFP into routine clinical practice can improve risk stratification, identify high-risk residual disease, and guide treatment decisions after LDT. 2. **Therapeutic Considerations:** - Patients with persistent AFP-L3+/DCP+ expression may benefit from earlier transition to systemic therapy or combination regimens, such as LDT with immunotherapy, as suggested by ongoing trials like EMERALD-01 and LEAP-012. - Intensified surveillance and more aggressive retreatment strategies may be warranted for biomarker-positive patients to prevent early progression. 3. **Personalized Treatment:** - Distinguishing between biomarker profiles (e.g., triple-negative, AFP-only, AFP-L3+/DCP+) can help tailor therapy to individual patient risk, optimizing outcomes and avoiding unnecessary interventions in lower-risk patients. ### Conclusion The study conclusively demonstrates that persistent AFP-L3 or DCP expression following LDT is a robust predictor of incomplete tumor response, rapid disease progression, and poor survival in unresectable HCC. These biomarkers provide critical prognostic information that complements imaging and liver function tests, offering a powerful tool for early risk stratification and personalized therapy planning.

MIER2 as a prognostic marker in colon adenocarcinoma

**MIER2 as a Prognostic Marker in Colon Adenocarcinoma (COAD)** **What is MIER2?** Mesoderm Induction Early Response 2 (MIER2) is a gene that has been identified to play a significant role in various biological processes, including cell signaling, immune modulation, and transcriptional regulation. In the context of colon adenocarcinoma (COAD), MIER2 has been discovered to act as an oncogenic regulator, meaning it promotes tumor progression and aggressiveness. It is significantly overexpressed in COAD tissues compared to normal tissues and has shown similar upregulation in other cancer types such as liver, stomach, and rectal adenocarcinoma. **Importance of Prognostic Markers in Colon Cancer** Prognostic markers are biological factors that help predict the likely course or outcome of a disease, such as cancer, independent of treatment. They are crucial in colon cancer for several reasons: 1. **Risk Stratification**: Prognostic markers help categorize patients into different risk groups, enabling personalized treatment strategies. 2. **Predicting Survival Outcomes**: They provide insights into overall survival (OS), disease-specific survival (DSS), and progression-free intervals (PFI), helping clinicians and patients understand the likely disease trajectory. 3. **Therapeutic Targeting**: Identifying novel biomarkers enables the development of targeted therapies, improving treatment efficacy and minimizing side effects. 4. **Improved Diagnosis**: Biomarkers can assist in early detection and diagnosis, which is critical for improving survival rates in highly malignant cancers like COAD. **How MIER2 Serves as a Prognostic Marker in COAD** 1. **Overexpression in COAD**: MIER2 is significantly upregulated in COAD tissues compared to normal tissues. This consistent overexpression across multiple datasets and cancer types highlights its potential as a robust biomarker. 2. **Correlation with Survival Outcomes**: High MIER2 expression is associated with significantly worse outcomes in COAD patients. Kaplan-Meier survival analysis revealed that patients with elevated MIER2 levels had reduced overall survival (OS), disease-specific survival (DSS), and progression-free intervals (PFI). 3. **Independent Prognostic Factor**: Multivariate Cox regression analysis confirmed that MIER2 is an independent predictor of poor prognosis in COAD, even after adjusting for other clinical factors like TNM stage, age, and sex. The adjusted hazard ratio (HR = 2.52, p < 0.001) underscores the strong prognostic value of MIER2. 4. **Nomogram Integration**: A prognostic nomogram was developed by integrating MIER2 expression with clinical variables (e.g., TNM stage). This tool accurately predicted 1-, 2-, and 3-year survival probabilities, with a high calibration accuracy (C-index = 0.754), further validating MIER2's utility in prognostication. 5. **Functional Role in Tumor Progression**: Functional studies demonstrated that MIER2 promotes tumor cell proliferation and migration in vitro. Knockdown of MIER2 in COAD cell lines (e.g., SW480) resulted in a 30–40% reduction in cell proliferation and migration, confirming its oncogenic role. **Comparison to Other Prognostic Markers** While other prognostic markers in COAD, such as KRAS, BRAF, and microsatellite instability (MSI) status, have been widely studied, MIER2 offers several unique advantages: 1. **Independent Prognostic Value**: Unlike some existing markers that depend on clinical stage or other factors, MIER2 independently predicts patient outcomes, making it a reliable standalone biomarker. 2. **Immune Modulation**: MIER2 is associated with significant changes in the tumor microenvironment, including increased CD8⁺ T cells and Tregs, and decreased CD4⁺ T cells, monocytes, and dendritic cells. This suggests that MIER2 not only affects tumor growth but also influences immune responses, providing a dual role as both a prognostic and immunological marker. 3. **Pathway Involvement**: MIER2 is linked to critical signaling pathways, such as the Notch and HIF-1 pathways, which are involved in tumor growth, immune evasion, and angiogenesis. This makes MIER2 a potential target for therapies aimed at these pathways. 4. **Potential for Therapeutic Targeting**: Unlike many traditional markers that are primarily diagnostic or prognostic, MIER2 appears to play a direct role in tumor biology. Silencing MIER2 not only reduces tumor aggressiveness but also triggers transcriptional reprogramming, including the activation of apoptosis and ER stress response pathways. This suggests that targeting MIER2 could have therapeutic benefits in addition to its prognostic utility. **Conclusion** MIER2 emerges as a promising prognostic marker in colon adenocarcinoma, with significant implications for patient stratification, survival prediction, and therapeutic targeting. Its ability to independently predict poor prognosis, along with its role in tumor progression and immune modulation, sets it apart from traditional prognostic markers in COAD. The findings from this study highlight the potential of MIER2 as a novel biomarker and therapeutic target, paving the way for improved diagnosis, prognostication, and personalized treatment strategies in colon cancer management.

Ferroptosis and enhances immunotherapy in pancreatic cancer

Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation and oxidative damage, has emerged as a potential mechanism to overcome the resistance of pancreatic ductal adenocarcinoma (PDAC) to immunotherapy. PDAC tumors are typically immune-cold, exhibiting poor CD8+ T-cell infiltration and resistance to immune checkpoint blockade (ICB), such as anti-PD-1 therapy. However, inducing ferroptosis can enhance tumor immunogenicity and sensitize PDAC to immunotherapy. Recent research has revealed that epigenetic regulation of the Nrf2–Slc40a1 axis plays a critical role in driving ferroptosis and improving immunotherapy outcomes in PDAC. The study utilized a patient-derived organoid (PDO) and autologous T-cell co-culture platform to identify compounds that synergize with anti-PD-1 therapy. Among 177 screened epigenetic modifiers, the histone demethylase inhibitor JIB04 emerged as the most effective agent, demonstrating the ability to enhance T-cell-mediated killing of PDAC cells. Mechanistically, JIB04 suppresses nuclear factor erythroid 2-related factor 2 (Nrf2), reducing chromatin accessibility of its downstream gene Slc40a1, which regulates iron efflux. This leads to intracellular iron accumulation, oxidative lipid damage, and ferroptosis. Ferroptotic cells exhibit markers such as malondialdehyde (MDA), reactive oxygen species (ROS), and lipid peroxidation, and release immunogenic signals (HMGB1, ATP, calreticulin) that activate dendritic cells and prime T-cells. In vivo studies confirmed that JIB04 enhances CD8+ T-cell infiltration, converts immune-cold PDAC tumors to immune-hot phenotypes, and improves anti-PD-1 efficacy without systemic toxicity. This ferroptosis-based epigenetic strategy represents a promising therapeutic avenue for sensitizing PDAC to immunotherapy and improving patient outcomes.

MATTERHORN Trial

The MATTERHORN trial was a global, Phase 3 study that investigated the addition of Durvalumab (an immunotherapy drug) to the standard FLOT chemotherapy regimen in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial aimed to evaluate whether this combination could improve survival outcomes and pathological responses. Participants were randomized into two groups: one received Durvalumab (1500 mg) combined with FLOT chemotherapy, while the other received a placebo with FLOT. FLOT chemotherapy was administered every two weeks for 4 cycles before surgery (neoadjuvant) and 2 cycles after surgery (adjuvant). After surgery, patients continued with Durvalumab or placebo every 4 weeks for up to 10 additional cycles, extending the immunotherapy treatment. The primary endpoint of the trial was Event-Free Survival (EFS), while secondary endpoints included pathological complete response (pCR), major pathological response (MPR), and Overall Survival (OS). PD-L1 expression (a biomarker) was also analyzed to assess its impact on treatment outcomes. Results showed that the combination of Durvalumab + FLOT significantly improved OS, with a 22% reduction in the risk of death compared to placebo + FLOT. EFS also improved, particularly in patients achieving a pathological response. Additionally, nodal downstaging (reduction in cancer spread to lymph nodes) was more frequent in the Durvalumab group (58.2% vs 44.8%). Importantly, the survival benefits were consistent across both high and low PD-L1 expression groups. The study concluded that Durvalumab + FLOT chemotherapy provides a meaningful survival benefit and may set a new standard of care for resectable gastric and GEJ adenocarcinomas.

Top 10 GI Oncology Studies at ESMO 2025

Based on the context provided, here are the top 10 gastrointestinal (GI) oncology studies that could be highlighted at ESMO 2025 based on their significant findings, clinical implications, and advancements in treatment strategies: --- ### **1. CheckMate-8HW (mCRC, 1L, MSI-H/dMMR)** - **Study Design:** Comparison of nivolumab + ipilimumab versus nivolumab alone in first-line microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). - **Key Findings:** - Significantly better progression-free survival (PFS) with dual-checkpoint blockade (HR ≈ 0.69). - Higher overall response rate (ORR) compared to nivolumab alone. - **Clinical Impact:** Confirms the advantage of dual immunotherapy in MSI-H/dMMR mCRC upfront, setting a new standard for first-line treatment in this subgroup. --- ### **2. STELLAR-303 (mCRC, previously treated, non-MSI-H)** - **Study Design:** Zanzalintinib (VEGFR/MET/AXL TKI) + atezolizumab versus regorafenib in previously treated non-MSI-H mCRC. - **Key Findings:** - Improved overall survival (OS) compared to regorafenib standard-of-care. - Demonstrates activity of VEGFR/MET/AXL-targeted therapy combined with PD-L1 blockade in proficient mismatch repair (pMMR) mCRC. - **Clinical Impact:** Signals potential for targeted therapy and immunotherapy combinations in later-line non-MSI-H mCRC treatment. --- ### **3. MATTERHORN (Resectable Gastric/GEJ Adenocarcinoma)** - **Study Design:** Peri-operative durvalumab + FLOT chemotherapy versus FLOT alone. - **Key Findings:** - Improved overall survival (OS) with the addition of durvalumab. - **Clinical Impact:** Supports integrating PD-L1 blockade into peri-operative FLOT for fit patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. --- ### **4. CASANDRA (Resectable/Borderline-Resectable Pancreatic Cancer)** - **Study Design:** Short-course PAXG regimen versus long-course modified FOLFIRINOX (mFOLFIRINOX). - **Key Findings:** - Event-free survival (EFS) improved with short-course nab-paclitaxel–based PAXG regimen. - **Clinical Impact:** Demonstrates that a shorter and more tolerable regimen can rival and outperform long-course mFOLFIRINOX for peri-operative control in pancreatic cancer. --- ### **5. GFH375X1201 (KRAS G12D-Mutant Pancreatic Cancer, Previously Treated)** - **Study Design:** KRAS-G12D inhibitor monotherapy. - **Key Findings:** - Objective response rate (ORR) ≈ 41%. - Median progression-free survival (PFS) ≈ 5.5 months. - **Clinical Impact:** Represents one of the strongest signals for a single-agent KRAS-targeted therapy in KRAS-G12D-mutant pancreatic ductal adenocarcinoma (PDAC). --- ### **6. KC-WISE (HER2+ Gastric/GEJ Cancer, Post-Trastuzumab)** - **Study Design:** Abemintamab (bispecific anti-HER2) + chemotherapy versus chemotherapy alone. - **Key Findings:** - Improved progression-free survival (PFS) and overall survival (OS). - **Clinical Impact:** Suggests durable benefit for next-generation HER2 bispecifics in HER2+ gastric/GEJ cancer after trastuzumab. --- ### **7. ZSAB-neoGOLP (Resectable High-Risk Intrahepatic Cholangiocarcinoma)** - **Study Design:** Neoadjuvant toripalimab (PD-1 inhibitor) + lenvatinib (VEGFR inhibitor) + GEMOX (gemcitabine + oxaliplatin) versus upfront surgery. - **Key Findings:** - Median event-free survival (EFS) of 18.0 months versus 8.7 months with upfront surgery. - **Clinical Impact:** Strengthens the case for integrating immunotherapy, targeted therapy, and chemotherapy in neoadjuvant settings for high-risk intrahepatic cholangiocarcinoma (iCCA). --- ### **8. FORTITUDE-101 (FGFR2b-Overexpressing Gastric/GEJ Cancer)** - **Study Design:** Bemarituzumab (anti-FGFR2b) + mFOLFOX6 chemotherapy in biomarker-selected patients. - **Key Findings:** - Statistically significant overall survival (OS) benefit at primary analysis. - **Clinical Impact:** Reinforces FGFR2b as a validated therapeutic target in gastric/GEJ cancer, particularly in biomarker-selected patients. --- ### **9. ABC-HCC (Intermediate-Stage, Unresectable Hepatocellular Carcinoma [HCC])** - **Study Design:** Atezolizumab (PD-L1 inhibitor) + bevacizumab (VEGF inhibitor) versus transarterial chemoembolization (TACE). - **Key Findings:** - Improved time-to-treatment failure (~14.6 months vs 9.5 months). - **Clinical Impact:** Positions immune-oncology (IO)-VEGF combinations as a potential alternative to TACE in intermediate-stage HCC (BCLC-B patients). --- ### **10. CITRIC (Chemorefractory RAS/BRAF Wild-Type mCRC)** - **Study Design:** Circulating tumor DNA (ctDNA)-guided anti-EGFR "re-challenge" strategy versus standard options. - **Key Findings:** - Improved progression-free survival (PFS) and overall survival (OS) in RAS/BRAF wild-type mCRC. - **Clinical Impact:** Validates liquid-biopsy–guided re-challenge with anti-EGFR therapy as an effective strategy in chemorefractory mCRC. --- ### Summary: These landmark studies represent significant advancements in GI oncology, spanning colorectal, gastric, pancreatic, cholangiocarcinoma, and hepatocellular cancers. They highlight the importance of personalized medicine, targeted therapies, novel combinations of immunotherapy, and the role of biomarkers in guiding treatment decisions. These findings are poised to reshape treatment paradigms and improve outcomes for patients across various GI malignancies. Let me know if you'd like me to prepare a one-page handout or slide summarizing this update for your meeting!

Prognostic and Predictive Impact of HER2 Alterations in mCRC Treated with Chemotherapy–Bevacizumab vs Anti-EGFR Therapy

The prognostic and predictive impact of HER2 alterations (amplification or mutation) in metastatic colorectal cancer (mCRC) was evaluated through a pooled analysis of eight major randomized clinical trials, involving 1,604 patients with RAS/BRAF wild-type, microsatellite-stable tumors. The key findings are as follows: ### Prognostic Impact: 1. **Prevalence of HER2 Alterations**: Approximately 5% of patients had HER2 amplification or overexpression, while about 2% harbored activating HER2 mutations. 2. **Worse Survival Outcomes**: Patients with HER2-positive tumors had significantly worse outcomes compared to HER2-negative patients: - **Progression-Free Survival (PFS)**: HER2-positive patients had a shorter PFS (9.8 months) compared to HER2-negative patients (12.2 months). - **Overall Survival (OS)**: HER2-positive patients had a reduced OS (28.0 months) compared to HER2-negative patients (34.9 months). 3. **HER2 Positivity as a Negative Prognostic Factor**: These survival differences persisted even after adjusting for covariates, confirming that HER2 positivity is an independent negative prognostic factor in mCRC. ### Predictive Impact: 1. **Objective Response Rates (ORR)**: The ORR was similar between HER2-positive and HER2-negative groups, indicating that HER2 status does not influence the initial response to treatment. 2. **Efficacy of Biologic Therapies**: - No significant interaction was observed between HER2 status and the efficacy of biologic therapies. - Patients with HER2 alterations derived comparable benefit from chemotherapy combined with either bevacizumab (anti-VEGF) or anti-EGFR agents. 3. **HER2-Mutant Tumors**: These tumors also demonstrated worse overall survival but did not show a differential response to biologic therapies. ### Conclusion: HER2 amplification or mutation is associated with poorer prognosis in mCRC but does not alter the efficacy of standard targeted therapies, such as chemotherapy with bevacizumab or anti-EGFR agents. These findings highlight the need for HER2-directed treatment strategies to improve outcomes in this subset of patients.

HCC outcome at the age of 80 and beyond with RF Ablation

The study conducted at Musashino Red Cross Hospital in Tokyo evaluated the effectiveness and safety of radiofrequency ablation (RFA) for treating hepatocellular carcinoma (HCC) in patients aged 80 years and older. The analysis included 518 patients, of which 136 were elderly (≥80 years) and 382 were younger (<80 years). All patients had tumors ≤3 cm and ≤3 nodules within the Milan criteria. Key findings for elderly patients (≥80 years) include: 1. **Overall Survival (OS)**: Median OS for elderly patients was 80 months, significantly shorter than the 123 months observed in younger patients (p=0.021). However, age itself did not significantly affect liver disease-related mortality. 2. **Recurrence-Free Survival (RFS)**: Median RFS was shorter for elderly patients (17 months) compared to younger patients (27 months), with a statistically significant difference (p=0.017). Elderly age was identified as a risk factor for recurrence. 3. **Prognostic Factors**: Poor survival and recurrence were associated with higher ALBI grade, elevated DCP levels (≥40 mAU/mL), persistent HCV infection, and nonviral liver disease. 4. **Safety and Complications**: RFA demonstrated acceptable safety with only 3.9% of patients experiencing complications (e.g., bleeding, pneumothorax, renal dysfunction), and no treatment-related deaths were reported. 5. **Clinical Implication**: Despite slightly shorter survival, RFA remains a viable, safe, and effective treatment for elderly HCC patients. Age ≥80 years did not significantly impact liver disease-specific mortality, indicating effective post-recurrence management.

Neoadjuvant immunotherapy Versus Surgery +/− Chemotherapy in High Resectable Gastroesophageal Adenocarcinoma

This study focused on comparing neoadjuvant immunotherapy using immune checkpoint inhibitors (ICIs) with surgery and/or chemotherapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma (GEA). These tumors are known to respond poorly to chemotherapy but are highly immunogenic, making immunotherapy a promising approach. The analysis included 197 patients divided into four groups: ICIs (49 patients), FLOT chemotherapy (27 patients), surgery alone (33 patients), and older chemotherapy regimens (88 patients). The study primarily assessed pathologic complete response (pCR) and major pathologic response (MPR) rates, alongside event-free survival (EFS) and overall survival (OS). Key findings showed that neoadjuvant ICIs resulted in significantly better tumor responses compared to chemotherapy. Patients treated with ICIs achieved a pCR rate of 61.9% versus 3.7% with FLOT chemotherapy, and an MPR rate of 78.6% versus 10%. Additionally, ICIs reduced residual nodal disease (ypN+) to 14.3% compared to 37% with chemotherapy, indicating superior tumor downstaging. Despite these impressive pathologic responses, survival outcomes (EFS and OS) were comparable between ICIs and surgery ± chemotherapy groups. At 36 months, EFS was 70.4% for ICIs versus 80.6% for surgery, and OS was 72.7% versus 90.4%. Patients with residual nodal disease (ypN+), advanced tumor stage (ypT4), or lack of pathologic response had worse survival outcomes. This study highlights neoadjuvant immunotherapy as a highly effective strategy for dMMR/MSI-H GEA, offering profound tumor regression and reduced reliance on chemotherapy. These findings support the potential for organ-sparing or non-surgical treatment approaches, paving the way for immunotherapy-centered management in this patient subgroup.

Anti-EGFRs and CRC

Anti-EGFR (epidermal growth factor receptor) therapies are a cornerstone of treatment for metastatic colorectal cancer (mCRC), particularly in patients with RAS/BRAF wild-type tumors. EGFR is a transmembrane receptor involved in cell growth, proliferation, and survival, and its dysregulation is a common feature in colorectal cancer. Below is a detailed explanation of how anti-EGFRs relate to colorectal cancer, focusing on their mechanisms, patient selection criteria, efficacy, and limitations: --- ### **Mechanism of Action** Anti-EGFR therapies target the EGFR receptor, blocking its activation by ligands such as EGF and TGF-alpha. This inhibition prevents downstream signaling through pathways like RAS-RAF-MAPK and PI3K-AKT, which are critical for tumor cell proliferation, survival, and metastasis. Common anti-EGFR monoclonal antibodies used in mCRC include: - **Cetuximab**: A chimeric monoclonal antibody. - **Panitumumab**: A fully human monoclonal antibody. --- ### **Patient Selection** Anti-EGFR therapies are only effective in certain subgroups of mCRC patients. Key criteria for their use include: 1. **RAS/BRAF Wild-Type Status**: - Patients with mutations in RAS (KRAS or NRAS) or BRAF genes are resistant to anti-EGFR therapy. Therefore, RAS/BRAF testing is mandatory before initiating treatment. - RAS mutations activate downstream signaling independent of EGFR, rendering anti-EGFR therapies ineffective. 2. **Tumor Sidedness**: - Tumor location (left-sided vs. right-sided) influences the efficacy of anti-EGFRs. Left-sided tumors (originating in the descending colon, sigmoid colon, or rectum) are generally more responsive to anti-EGFR therapy. Right-sided tumors (from the ascending colon or cecum) show poorer outcomes with these agents. 3. **Microsatellite Stability (MSS)/Mismatch Repair Proficiency (pMMR)**: - Anti-EGFR therapies are typically used in MSS/pMMR tumors, as microsatellite instability-high (MSI-H) tumors are more likely to benefit from immunotherapy. 4. **HER2 Status**: - HER2-positive tumors were historically thought to be resistant to anti-EGFR therapy. However, recent findings suggest HER2 status does not predict response to anti-EGFRs, although HER2-positive tumors are associated with worse prognosis overall. --- ### **Efficacy** Anti-EGFR therapies have shown significant benefits in terms of tumor shrinkage and survival in appropriately selected patients: - **Objective Response Rates (ORR)**: For RAS/BRAF wild-type left-sided tumors, ORR with anti-EGFR therapy can reach up to 60-70%. - **Progression-Free Survival (PFS)**: Anti-EGFR therapies improve PFS when combined with chemotherapy, such as FOLFIRI (5-FU, leucovorin, and irinotecan) or FOLFOX (5-FU, leucovorin, and oxaliplatin). - **Overall Survival (OS)**: Studies have shown improved OS in RAS/BRAF wild-type patients treated with anti-EGFRs compared to non-targeted therapies. --- ### **Limitations** Despite their benefits, anti-EGFR therapies have notable limitations: 1. **Resistance Mechanisms**: - Primary resistance occurs in patients with RAS/BRAF mutations or other alterations like HER2 amplification, PIK3CA mutations, or EGFR extracellular domain mutations. - Acquired resistance can develop during treatment due to clonal evolution, often involving secondary mutations in the EGFR pathway. 2. **Side Effects**: - Common adverse effects include skin toxicity (rash), hypomagnesemia, and infusion-related reactions. 3. **Limited Efficacy in Right-Sided Tumors**: - Right-sided mCRC tumors generally have worse outcomes with anti-EGFR therapy, likely due to distinct biological characteristics. 4. **Cost**: - Anti-EGFR therapies are expensive and may not be accessible in all healthcare settings. --- ### **Clinical Trials and Recent Findings** Recent studies have explored the role of anti-EGFR therapies in combination or sequential therapy settings: - **TRIBE2 Trial**: Demonstrated that bevacizumab-based therapies may be preferred for certain patients, but anti-EGFRs remain effective in RAS/BRAF wild-type left-sided tumors. - **PARADIGM Trial**: Highlighted the importance of tumor sidedness in guiding the choice between anti-EGFR and bevacizumab. - **CALGB/SWOG80405 Trial**: Compared anti-EGFRs and bevacizumab in first-line settings, showing similar efficacy overall but better outcomes with anti-EGFRs for left-sided tumors. --- ### **Future Directions** Anti-EGFR therapies remain an integral part of mCRC treatment, but ongoing research aims to refine their use: 1. **Biomarker Development**: - Identification of additional biomarkers (e.g., HER2, EGFR mutations, ctDNA profiling) to predict response and resistance. 2. **Combination Therapies**: - Combining anti-EGFRs with other targeted agents, such as HER2 inhibitors or immune checkpoint inhibitors, for specific molecular subgroups. 3. **Personalized Medicine**: - Leveraging next-generation sequencing (NGS) to tailor therapies based on individual tumor profiles. --- ### **Conclusion** Anti-EGFR therapies are highly effective in RAS/BRAF wild-type, left-sided mCRC, offering significant survival benefits. However, their efficacy is influenced by tumor biology, sidedness, and molecular alterations. While HER2 status does not predict benefit from anti-EGFR therapy, HER2-positive tumors represent a poor-prognosis subgroup that may benefit from HER2-targeted approaches in the future. Continued research and clinical trials are essential to optimize anti-EGFR use and improve outcomes for mCRC patients.

Pancreatic Cancer and mRNA Vaccines

Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 13% due to its aggressive nature and high recurrence rates even after surgery. Traditional treatments like chemotherapy, radiation, and immunotherapy have limited success because of the tumor's dense microenvironment and low visibility to the immune system. To address these challenges, researchers at Memorial Sloan Kettering (MSK) developed a personalized mRNA vaccine, autogene cevumeran, designed to train the immune system to recognize tumor-specific mutations (neoantigens). In a Phase I trial, 16 patients with surgically removed pancreatic cancer received a custom mRNA vaccine along with checkpoint inhibitor atezolizumab and chemotherapy. Tumor DNA was sequenced to identify neoantigens, which were encoded into an mRNA molecule and delivered via lipid nanoparticles. This vaccine successfully triggered T-cell responses in half the patients. Among responders, six out of eight remained cancer-free after three years, while non-responders experienced earlier recurrence, showing a strong link between immune activation and clinical outcomes. The vaccine-induced T cells demonstrated long-term memory, essential for sustained cancer control. The process was rapid, with vaccine production taking an average of nine weeks. However, patients without spleens showed reduced immune responses, highlighting the spleen's role in vaccine efficacy. This personalized approach showed safety, tolerability, and promise for treating not just pancreatic cancer but other resistant cancers like glioblastoma. Ongoing Phase II trials aim to validate these findings, offering hope for durable, individualized cancer treatments and advancing the future of precision medicine.